GBMA is an associate member of the International Generic and Biosimilar Medicines Association (IGBA)
Originally called the International Generic Pharmaceutical Alliance (IGPA), IGBA was founded in March 1997 as an international network of generic medicines associations. The name of the organization was changed in September 2015 to the International Generic and Biosimilar Medicines Association to reflect the evolving nature of the industry.
IGBA is committed to promoting generic and biosimilar medicines, and exchanging information worldwide. IGBA consists of the following associations:
- Canadian Generic Pharmaceutical Association (CGPA-Canada)
- Medicines for Europe (Europe)
- Generic Pharmaceutical Association (GPhA-USA)
- Japan Generic Medicines Association (JGA-Japan)
- Jordanian Association of Pharmaceutical Manufacturers (JAPM-Jordan)
- National Association of Pharmaceutical Manufacturers (NAPM-South Africa)
- Taiwan Generic Pharmaceutical Association (TGPA-Taiwan)
- In addition, the generic medicines associations of Australia, Brazil and Mexico are Associate Members
Through its constituent member associations, the IGBA maintains constant dialogue with the ICH, WHO, WTO, WIPO and other international organizations.
IGBA members share a set of common principles:
Access to affordable quality medicines
- We believe that seeking to improve access to affordable quality medicines worldwide and promote the quality, safety and efficacy of generic medicines is of utmost importance.
Ensure timely access for patients
- We all know how difficult it is to strike a balance between patent protection and free competition, which is why achieving balanced intellectual property rights in our sector will ensure timely access for patients to our products.
Global harmonisation of regulations relating to quality
- A top priority is to promote the global harmonisation of regulations relating to the quality of generic products, especially ensuring strict adherence to bioequivalence standards.
Improving regulatory and legal expertise
- We have worked very hard to provide guidance to international organisations and national governments to improve their regulatory and legal expertise relating to the manufacture, registration and marketing of high quality generic medicines, and promotion of uniform and effective GMP standards and quality controls.
Prevent the production and trade of counterfeit versions
- We are concerned with the counterfeiting of medicines, which is a criminal act that puts the health and life of patients in jeopardy. As an alliance, we are fighting in favour of strict and effective regulatory controls to prevent the production and trade of counterfeit versions of all medicines and their APIs.